Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Resistance and CNS Function in Type 2 Diabetes
NCT00212290Phase 4Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Nov 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pioglitazone, nateglinide in type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Nov 2002; status: completed.
02
Drugs
pioglitazonenateglinide
03
Conditions
type 2 diabetes mellitus (T2DM)impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT00212290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00212290.